Inspirna, Inc.

📍 New York, United States🗓 Founded 2010👥 28 employees💰 Last funded 2022
Biotechnology🌐 inspirna.com
Website LinkedIn
Inspirna is developing first-in-class drugs that target key pathways in cancer progression. Using a discovery platform developed by Inspirnas founding scientists at Rockefeller University, we have discovered several novel cancer targets that drive tumor growth and cancer progression. These targets regulate key components of the tumor micro-environment including immune cells and cancer metabolism pathways. Our discovery platform - which can be applied to virtually any tumor type - has yielded novel therapeutic targets for several high-unmet need cancer types to date. We aim to develop effective therapies against these targets that will provide durable and meaningful responses for cancer patients that lack effective therapies. Our lead therapy RGX-104 is a small molecule immunotherapy that blocks the ability of tumors to evade the immune system. RGX-104 has obtained FDA Orphan Drug Designation in several solid tumor types of high-unmet need and entered clinical trials in Q4 2016.
2
Total investors
0
Early stage
0
Mid stage
1
Late stage
2010
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Inspirna, Inc.?
Inspirna, Inc. has 2 investors on record on gritt.io and 1 late-stage investors.
When did Inspirna, Inc. last raise funding?
The most recent investment in Inspirna, Inc. recorded on gritt.io was in 2022.
When was Inspirna, Inc. founded?
Inspirna, Inc. was founded in 2010.
What industry is Inspirna, Inc. in?
Inspirna, Inc. operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Inspirna, Inc. based?
Inspirna, Inc. is headquartered in New York, United States.